HOYA Vision Care Translates Available Evidence into Everyday Practice at the ECLSO 2024

BANGKOK – 30 April 2024 HOYA Vision Care, committed to sharing knowledge and technological advances in the myopia field, was delighted to take part in the 50th European Contact Lens Society of Ophthalmologists (ECLSO) congress, which took place on 26th and 27th of April 2024 in Istanbul. As a prominent figure in myopia management, HOYA made its debut as a platinum sponsor this year.


Myopia management is a rapidly developing field, with increasing number of new products reaching the market each year. As such, evidence is becoming more and more important to help ensure Eye Care Professionals are equipped with proven and effective solutions for treatment of their patients. That’s why HOYA Vision Care hosted a symposium named Confidence through Evidence – MiYOSMART in daily practice, highlighting the rich body of evidence behind the efficacy of MiYOSMART spectacle lenses and how this information may be transferred to real-life practice.


The symposium, split into two parts, was started by Pascal Blaser, Global Professional Affairs Manager at HOYA Vision Care, highlighting the key clinical studies demonstrating the long-term efficacy of the MiYOSMART spectacle lenses.Following this presentation, Professor Hakan Kaymak addressed the question, "Can we achieve a 100% treatment effect in myopia control?", bridging the gap between research findings and practical application in daily practice. Professor Kaymak used findings from a 2-year randomised controlled trial from 20191 to assess the impact of MiYOSMART spectacle lenses on axial length growth using age-matched analyses. The age-matched myopia control (AMMC) tool allows studies to be compared in terms of their therapeutic success and takes age-related physiological changes in growth into account. The final findings of Professor Kaymak’s analysis showed that only D.I.M.S. Technology exhibited physiological axial length growth long-term; a finding likely to influence treatment decisions in everyday practice moving forward.


On the second day during the innovation session, Marianne Goldwaser, Global Professional Affairs Manager at HOYA Vision Care, presented MiYOSMART Sun solutions which have been launched in 2023.


Over 7 million MiYOSMART spectacle lenses have already sold worldwide since their launch in 2018.2 HOYA Vision Care will continue to help fight and control the growing problem of myopia around the world by continually growing MiYOSMART evidence and sharing industry knowledge in the field of myopia treatment.


Disclaimer: MiYOSMART is not approved for myopia management in all countries, including the United States, and is not currently available for sale in all countries, including  the United States.

“Together, we can tackle myopia in children”


About HOYA Vision Care

As a global leader in optical technology, HOYA Vision Care is dedicated to providing innovative vision care solutions for every stage of a patient’s life. A steadfast partner to Eye Care Professionals around the world, it stands at the forefront of optical excellence. With a global presence, consisting of 43 laboratories and a growing team of 20,000 employees, HOYA Vision Care delivers innovative lenses and other vision care solutions to millions of people in 110 countries.

About HOYA


  1. Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-368.
  2. Based on number of MiYOSMART spectacle lenses sold as per HOYA sales data on file as of December 2023.

Keeping in the know

The Latest News from MiYOSMART

Stay up to date with latest news from MiYOSMART